Trial Profile
A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2019
Price :
$35
*
At a glance
- Drugs Vecabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Sunesis Pharmaceuticals
- 06 Nov 2019 Results (n=27) assessing safety, pharmacokinetics, pharmacodynamics, maximum tolerated dose and antitumor activity of oral vecabrutinib in adult patients with relapsed/refractory advanced B-cell malignancies, released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 05 Dec 2016 Results published in a Sunesis Pharmaceuticals media release.